Later attempts at utilising anti-idiotypic mAbs in a phase I trial of 25 patients with stage IV melanoma employed the MK2-23 anti-idiotypic mAb, which recognises the 763.74 anti-CSPG4 clone. Here, CSPG4 is linked to melanoma.